First-in-human Dose-Escalation Trial of BI 764532, a Delta-Like Ligand 3 (DLL3)/CD3 IgG-like T-cell Engager in Patients (pts) with DLL3-positive (DLL3+) Small-Cell Lung Cancer (SCLC) and Neuroendocrine Carcinoma (NEC)